Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley
Primary Purpose
Malignant Neoplasms of Female Genital Organs
Status
Active
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Proflavine
High-Resolution Microendoscopy (HRME)
Sponsored by
About this trial
This is an interventional prevention trial for Malignant Neoplasms of Female Genital Organs focused on measuring Malignant neoplasms of female genital organs, Cervical Cancer Prevention, Abnormal Pap test, Positive HPV test, History of cervical dysplasia, Colposcopy, Proflavine, Proflavine hemisulfate, High-Resolution Microendoscopy, HRME, Human papillomavirus
Eligibility Criteria
Inclusion Criteria:
- Women with an abnormal Pap test, positive HPV test or any history of cervical dysplasia
- Women with an intact cervix (patients who have undergone previous LEEP, cone and/or cryotherapy are eligible)
- Women of childbearing potential must have a negative urine or serum pregnancy test
- Women who are at least 21 years of age or older
- Ability to understand and the willingness to provide informed consent and sign a written Informed Consent Document (ICD)
- For patients that present to clinic to have a cervical excisional procedure (LEEP) for an already confirmed diagnosis of high grade cervical dysplasia, HRME imaging study will be performed and cervical biopsies might be taken for research purposes only. Since these patients have already the confirmed diagnosis of high-grade cervical dysplasia, any extra biopsies taken will be for research purposes only and our research fund will pay them
Exclusion Criteria:
- Women < 21 years of age
- Women who have undergone a hysterectomy with removal of the cervix
- Women with a known allergy to proflavine, acriflavine, or iodine
- Women who are pregnant or nursing
- Patients unable or unwilling to provide informed consent or sign a written Informed Consent Document (ICD)
Sites / Locations
- University of Texas Medical Branch Cancer Stop McAllen Clinic
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
High-Resolution Microendoscopy (HRME)
Arm Description
After standard colposcopy examination performed, participants undergo a high-resolution microendoscopy imaging procedure. Proflavine 0.01% is applied to the cervix, then high-resolution microendoscopy imaging procedure performed. Standard colposcopy procedure will then continue.
Outcomes
Primary Outcome Measures
Diagnostic Accuracy of the High-Resolution Microendoscopy (HRME)
Successful outcome defined as concordance between the diagnosis using HRME imaging and the most severe histologic diagnosis.
Secondary Outcome Measures
Full Information
NCT ID
NCT02714439
First Posted
March 16, 2016
Last Updated
August 8, 2023
Sponsor
The University of Texas Medical Branch, Galveston
Collaborators
M.D. Anderson Cancer Center, The University of Texas Health Science Center, Houston, William Marsh Rice University
1. Study Identification
Unique Protocol Identification Number
NCT02714439
Brief Title
Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley
Official Title
Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
October 25, 2016 (Actual)
Primary Completion Date
July 1, 2025 (Anticipated)
Study Completion Date
July 1, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The University of Texas Medical Branch, Galveston
Collaborators
M.D. Anderson Cancer Center, The University of Texas Health Science Center, Houston, William Marsh Rice University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate a different type of medical equipment called "High-Resolution Microendoscope" (HRME) for the diagnosis of cervical pre-cancerous lesions and cervical cancer. The investigators want to compare patients' clinical findings using the current equipment used in clinic with the clinical findings using new equipment we are testing on this research project. If the new equipment is proven to give comparable findings with current equipment being used, doctors might be able to offer a diagnosis and treat cervical lesions in one visit. It might not be necessary to wait for cervical biopsies to come back before women would receive the indicated treatment. Study subjects are being asked to participate because they have been diagnosed with an abnormal Papanicolaou (Pap) PAP smear, positive human papillomavirus (HPV) test or history of cervical dysplasia and need to have a colposcopic examination to determine the reason for abnormal results and receive treatment.
Detailed Description
Investigators will start the participants' examination with colposcopic evaluation using current equipment as determined by standard of care. But, if cervical biopsies are indicated, before performing biopsies, for research purposes only - investigators will:
Apply a substance called Proflavine 0.01% to participants' cervix
Investigators will re-evaluate participants' cervix with the new equipment being tested:The High- Resolution Microendoscope
After completing this re-evaluation, investigators will continue with the standard of care protocol and will perform participants' cervical biopsies if indicated.
The entire re-evaluation with the new equipment should add less than 10 minutes to the standard examination.
When a woman is found to have an abnormal PAP smear, depending on the findings and clinical history, most women will need to be further evaluated with a colposcope in order to understand the reason for the abnormal PAP and determine the best treatment. This is called colposcopic examination and it is the standard of care. This procedure is performed in the clinic, patient is positioned on the examining table the same way she is positioned for a Papanicolaou (Pap) smear, a speculum is placed inside the vaginal canal, and certain substances are applied to the cervix in order to identify cervical lesions. These substances might include acetic acid and/or Lugol's iodine solution. The application of these substances helps to delineate the abnormal cervical areas that might need to be biopsied. For the purpose of this research study, before obtaining the biopsies, a second evaluation will be performed using the equipment that is being studied (High- Resolution Microendoscope) and using a different substance that will be applied to the cervix. This substance is called Proflavine 0.01%. . This second evaluation should not take more than 10 minutes. After completing this second evaluation, participants' clinical examination and clinical visit should continue as routine.
The anticipated total number of subjects involved in the study will be 150 women. All these anticipated participating women would be from The University of Texas Medical Branch (UTMB), Su Clinica and UT Health Science Center (UT-HSC) Mobile Van. The length of time for participation is 1 year. However, during the participants' year of enrollment she might have only one examination, during one of her visits,using the research equipment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malignant Neoplasms of Female Genital Organs
Keywords
Malignant neoplasms of female genital organs, Cervical Cancer Prevention, Abnormal Pap test, Positive HPV test, History of cervical dysplasia, Colposcopy, Proflavine, Proflavine hemisulfate, High-Resolution Microendoscopy, HRME, Human papillomavirus
7. Study Design
Primary Purpose
Prevention
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
150 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
High-Resolution Microendoscopy (HRME)
Arm Type
Experimental
Arm Description
After standard colposcopy examination performed, participants undergo a high-resolution microendoscopy imaging procedure. Proflavine 0.01% is applied to the cervix, then high-resolution microendoscopy imaging procedure performed. Standard colposcopy procedure will then continue.
Intervention Type
Drug
Intervention Name(s)
Proflavine
Other Intervention Name(s)
Proflavine hemisulfate
Intervention Description
Proflavine 0.01% applied to the cervix before high-resolution microendoscopy imaging procedure performed.
Intervention Type
Procedure
Intervention Name(s)
High-Resolution Microendoscopy (HRME)
Intervention Description
High-resolution microendoscopy imaging procedure performed after colposcopy exam. Standard colposcopy procedure will then continue. Entire HRME imaging procedure should add less than 10 minutes to the standard colposcopy exam.
Primary Outcome Measure Information:
Title
Diagnostic Accuracy of the High-Resolution Microendoscopy (HRME)
Description
Successful outcome defined as concordance between the diagnosis using HRME imaging and the most severe histologic diagnosis.
Time Frame
1 day
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Women with an abnormal Pap test, positive HPV test or any history of cervical dysplasia
Women with an intact cervix (patients who have undergone previous LEEP, cone and/or cryotherapy are eligible)
Women of childbearing potential must have a negative urine or serum pregnancy test
Women who are at least 21 years of age or older
Ability to understand and the willingness to provide informed consent and sign a written Informed Consent Document (ICD)
For patients that present to clinic to have a cervical excisional procedure (LEEP) for an already confirmed diagnosis of high grade cervical dysplasia, HRME imaging study will be performed and cervical biopsies might be taken for research purposes only. Since these patients have already the confirmed diagnosis of high-grade cervical dysplasia, any extra biopsies taken will be for research purposes only and our research fund will pay them
Exclusion Criteria:
Women < 21 years of age
Women who have undergone a hysterectomy with removal of the cervix
Women with a known allergy to proflavine, acriflavine, or iodine
Women who are pregnant or nursing
Patients unable or unwilling to provide informed consent or sign a written Informed Consent Document (ICD)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ana M Rodriguez, MD
Organizational Affiliation
University of Texas Medical Branch (UTMB)
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kathleen Schmeler, MD
Organizational Affiliation
M.D. Anderson Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Texas Medical Branch Cancer Stop McAllen Clinic
City
McAllen
State/Province
Texas
ZIP/Postal Code
78501
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Links:
URL
http://www.utmb.edu
Description
University of Texas Medical Branch web site
Learn more about this trial
Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley
We'll reach out to this number within 24 hrs